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av2 is a widely expressed Rho family guanine nu-
cleotide exchange factor highly homologous to
Vav1 and Vav3. Activated versions of Vav2 are trans-
forming, but the normal function of Vav2 and how it is reg-
ulated are not known. We investigated the pathways that
regulate Vav2 exchange activity in vivo and characterized
its function. Overexpression of Vav2 activates Rac as as-
sessed by both direct measurement of Rac-GTP and cell
morphology. Vav2 also catalyzes exchange for RhoA, but
does not cause morphologic changes indicative of RhoA
activation. Vav2 nucleotide exchange is Src-dependent in
vivo, since the coexpression of Vav2 and dominant nega-
tive Src, or treatment with the Src inhibitor PP2, blocks
both Vav2-dependent Rac activation and lamellipodia for-
mation. A mutation in the pleckstrin homology (PH) do-
V
 
main eliminates exchange activity and this construct does
not induce lamellipodia, indicating the PH domain is nec-
essary to catalyze nucleotide exchange. To further investi-
gate the function of Vav2, we mutated the dbl homology
(DH) domain and asked whether this mutant would func-
tion as a dominant negative to block Rac-dependent
events. Studies using this mutant indicate that Vav2 is not
necessary for platelet-derived growth factor– or epidermal
growth factor–dependent activation of Rac. The Vav2 DH
mutant did act as a dominant negative to inhibit spreading
of NIH3T3 cells on ﬁbronectin, speciﬁcally by blocking
lamellipodia formation. These ﬁndings indicate that in ﬁ-
broblasts Vav2 is necessary for integrin, but not growth fac-
tor–dependent activation of Rac leading to lamellipodia.
 
Introduction
 
Rho family GTP-binding proteins (GTPases) mediate nu-
merous cellular events, including the regulation of actin
structures, adherence and motility, gene transcription, and
cell cycle progression (Hall, 1998). GTPases undergo a con-
formational change upon GTP binding that allows them to
interact with effector molecules and thereby transmit signals.
The exchange of GTP for GDP is the critical step in initiat-
ing signaling and is catalyzed by guanine nucleotide ex-
change factors (GEFs)* (Cerione and Zheng, 1996). Thus,
understanding how RhoGEFs are regulated is critical to pro-
viding insight into how Rho family GTPases function.
There are 
 
 
 
30 RhoGEFs, all of which contain a DH do-
main, which is necessary to catalyze nucleotide exchange,
and an adjacent PH domain (Whitehead et al., 1997). The
PH domains in some proteins, including RhoGEFs, bind
phosphoinositides and mediate membrane localization (Bot-
tomley et al., 1998). The PH domain of some RhoGEFs is
necessary for nucleotide exchange (Freshney et al., 1997).
The large number of RhoGEFs and their overlapping speci-
ficities for GTP binding proteins raise the questions of how
Rho family–dependent functions are coordinated in vivo
and whether RhoGEFs are redundant or have specific func-
tions. Although RhoGEFs have been extensively studied,
these questions remain largely unanswered.
The RhoGEF Vav1 has been well characterized and two
other mammalian family members have been identified re-
cently, Vav2 and Vav3 (Katzav et al., 1989; Henske et al.,
1995; Schuebel et al., 1996; Trenkle et al., 1998; Movilla
and Bustelo, 1999). The expression of Vav proteins is highly
conserved: both 
 
Caenorhabditis elegans
 
 and 
 
Drosophila mela-
nogaster
 
 have Vav homologues (Dekel et al., 2000). All
mammalian Vav proteins share the same domain structure.
Within the NH
 
2 
 
terminus of Vav family members is an
acidic domain and a region related to calponin that is
present in some actin binding proteins. These domains are
followed by the DH and PH domains and a COOH termi-
nus with a cysteine-rich region and a single SH2 domain
flanked by SH3 domains.
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A truncated form of Vav1 was originally identified as an
oncogene and Vav1 is expressed primarily in the hematopoi-
etic system, as well as in the pancreas and lung (Bustelo et al.,
1993). Vav1 activates Rac1 and perhaps RhoA and Cdc42
(Crespo et al., 1997; Han et al., 1997). Vav2 is widely ex-
pressed in tissues and cell lines. The literature is inconsistent
with regards to the GTPases activated by Vav2. Schuebel et
al. (1998) reported that Vav2 catalyzed exchange for RhoA,
RhoB, and RhoG in vitro, whereas Abe et al. (2000) re-
ported that Vav2 catalyzed exchange for Rac1, RhoA, and
Cdc42 in vitro. The development of assays based on the
known binding interaction between Rac/Cdc42 and p21-
activated kinase (PAK) binding domain (PBD) (Sander et al.,
1998), and based on the known binding interaction between
RhoA and the Rho binding domain (RBD) of rhotekin (Ren
et al., 1999), has permitted the determination of Vav2 ex-
change activity in vivo. Liu and Burridge (2000) showed that
Vav2 is an exchange factor for Rac1, Cdc42, and RhoA in
CHO cells in vivo using these assays. Vav3 is expressed pre-
dominantly in brain and hematopoietic cells and to a lesser
extent in other tissues, and activates RhoG, RhoA, and Rac1
in vitro (Movilla and Bustelo, 1999; Trenkle et al., 2000)
and RhoA and Rac1 in vivo (Zeng et al. 2000).
Tyrosine phosphorylation is necessary for the exchange ac-
tivity of the Vav proteins in vitro and has been used as a sur-
rogate for activation in vivo (Crespo et al., 1997). Vav1 is ty-
rosine phosphorylated in response to many signals, including
B or T cell receptor activation and integrin cross-linking in
myeloid cells and platelets (Bustelo, 2000). The kinases that
phosphorylate Vav1 include Syk in B cells, Zap70 and Fyn in
T cells, and Janus kinases in response to cytokine receptor
stimulation (Bustelo, 2000; Huang et al., 2000). Vav proteins
are also tyrosine phosphorylated in response to growth factor
stimulation, including EGF, PDGF, and insulin (Bustelo et
al., 1992; Moores et al., 2000; Pandey et al., 2000). Src fam-
ily kinases phosphorylate and activate Vav proteins in vitro,
but their role in Vav function in vivo is not established. Phos-
phorylation of Y174 stimulates exchange activity in vitro
(Han et al., 1997) by disrupting the inhibitory interaction of
Y174 with the DH domain (Aghazadeh et al., 2000). Muta-
tion of Y174 to F activates Vav1, which likely reflects the in-
ability of F174 to bind to and inhibit the DH domain (Lo-
pez-Lago et al., 2000). The Y174F mutant is activated to the
same extent as wild-type Vav1 by tyrosine phosphorylation in
in vitro exchange assays, indicating that an additional site(s) is
phosphorylated to stimulate exchange activity.
Vav proteins activate pathways dependent on Rho family
GTP-binding proteins, including protein kinases in the mi-
togen-activated protein kinase and PAK families, actin rear-
rangement, and stimulation of transcription by serum re-
sponse factor and nuclear factor kappa B (Bustelo, 2000).
Interestingly, the activation of nuclear factor of activated T
cells does not require the exchange activity of Vav1 (Kuhne
et al., 2000). In contrast, Vav2 potentiation of nuclear factor
of activated T cells requires exchange activity in B cells
(Doody et al., 2000). Studies of cells from mice lacking Vav1
indicate that Vav1 is critical for B and T cell signaling (Fi-
scher et al., 1995, 1998; Tarakhovsky et al., 1995; Zhang et
al., 1995; Turner et al., 1997). B cells from Vav
 
 
 
/
 
 
 
 mice have
a defective proliferative response to B cell receptor activation
and fail to mount an immune response to nonrepetitive anti-
gens. Cytotoxic T cells from Vav
 
 
 
/
 
 
 
 mice show a reduction
in CD3- plus CD28-mediated proliferation, a decrease in IL-2
production, and a reduction in cytotoxic T cell responses.
Little is known about the biological roles of Vav2 or Vav3.
To better understand the function of Vav2, we deter-
mined the GTPases activated by Vav2 in vivo and investi-
gated the role of Src and the Vav2 DH and PH domains in
regulating Vav2 exchange activity. We used a mutant form
of Vav2 that lacks exchange activity to inhibit the function
of endogenous Vav2 and found that this mutant blocked
spreading of NIH3T3 cells on fibronectin. The cells form
filopodia, but do not form lamellipodia. This mutant did
not block Rac-dependent effects of PDGF or EGF, suggest-
ing that Vav2 is necessary for integrin-dependent activation
of Rac during cell spreading, but not for growth factor–
dependent Rac activation.
 
Results
 
Exchange activity of Vav2
 
An important step in understanding the function of Vav2 is
to determine the GTPases it activates. Studies of the ex-
change activity of Vav2 in vitro have yielded conflicting re-
sults, as discussed above. Recently, assays have been de-
scribed that allow measurement of Rac, Cdc42, and RhoA
activation in vivo
 
 
 
(Sander et al., 1998; Ren et al., 1999). We
used these assays to determine the GTP binding proteins ac-
tivated by Vav2 expression in vivo. NIH3T3 fibroblasts
were transfected with Vav2 and myc-Rac, hemagglutinin
(HA)-Cdc42, or HA-RhoA. Cells were harvested after 24 h,
lysed, and incubated with glutathione 
 
S
 
-transferase (GST)-
PBD or GST-RBD bound to glutathione agarose beads. The
amount of activated Rac, Cdc42, or RhoA was determined
by probing the Western blots for the GTPases associated
with the GST-PBD or GST-RBD constructs. Vav2 acti-
vated Rac1 (Fig. 1 A) and to a lesser extent RhoA (Fig. 1 D),
but we detected minimal activation of Cdc42, although Dbl
did activate Cdc42 as expected (Fig. 1 C). Similar results
were obtained when the experiments were done using
HEK293T or Cos7 cells. We also compared activation of
endogenous Rac by Vav2 and Vav1 and detected a similar
extent of activation (Fig. 1 B).
 
Vav2 induces lamellipodia and activation of Jnk
 
Since we detected activation of Rac and Rho by Vav2 we in-
vestigated the effects of overexpressing Vav2 on actin struc-
tures in NIH3T3 cells to determine whether the phenotype
suggested a predominance of either Rac or Rho activation.
Overexpression of Vav2 resulted in extensive lamellipodia in
80% of transfected cells (Fig. 2 A). No untransfected cells
had the extensive lamellipodia seen in the Vav2 transfected
cells and less than 20% of untransfected cells had any lamel-
lipodia. These results are similar to Moores et al. (2000), but
in contrast to Schuebel et al. (1998), who reported that
overexpression of wild-type Vav2 had no effect on actin. We
detected few cells that had prominent stress fibers or were
contracted, suggesting that under these conditions there was
little activation of RhoA relative to Rac. We also assayed Jnk
activity in COS7 cells transfected with Vav2 and found that 
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overexpression of Vav2-activated Jnk (Fig. 2 B). Since acti-
vation of Jnk in COS7 cells is dependent on Rac or Cdc42
but not Rho (Coso et al., 1995), and we detect minimal acti-
vation of Cdc42 by Vav2, stimulation of Jnk by Vav2 in
COS7 cells indicates that Vav2 activates Rac in vivo.
We used a Vav2 construct containing the T7 epitope at the
COOH terminus in overexpression studies. Since overex-
pression of wild-type Vav2 alone activated Rac1, we wanted
to be certain that the T7 epitope tag did not stimulate Vav2.
NIH3T3 cells were cotransfected with either T7-tagged or
untagged Vav2 and an enhanced green fluorescent protein
(pEGFP) to identify the transfected cells, and the number of
transfected cells with lamellipodia were counted. Both un-
tagged and T7Vav2 constructs caused 
 
 
 
80% of the trans-
fected cells to form lamellipodia (data not shown), indicating
that the epitope tag does not activate Vav2.
 
Src is necessary for Vav2 activity
 
Coexpression of activated Lck with wild-type Vav2 pro-
motes colony formation and induces lamellipodia (Schuebel
et al., 1998), and the exchange activity of Vav proteins is ac-
tivated by Src-like kinases in vitro, but it is not known
whether Src kinases are necessary for Vav2 activation in
vivo. To determine whether Src family members are neces-
sary for Vav2 activity, HEK293T cells were transfected with
Vav2 and kinase-dead (KD) Src, and Rac activation was
compared with cells transfected with Vav2 alone. As shown
in Fig. 3 A, KD Src blocked Vav2-dependent Rac activation.
We did not detect increased Rac activation when Vav2 was
cotransfected with activated Src, although Vav2 tyrosine
phosphorylation was increased (data not shown), indicating
that endogenous Src activity is sufficient to fully activate
Vav2. We also determined the effect of KD Src and the Src
inhibitor, PP2, on the formation of Vav2-dependent lamel-
lipodia. NIH3T3 were transfected with Vav2 and KD Src or
with Vav2 alone and treated with PP2. PP2 treatment or
cotransfection of Vav2 and KD Src reduced the number of
Vav2 transfected cells with lamellipodia by 80 and 70%, re-
spectively, and in those cells in which lamellipodia were
present, they were much less prominent (Fig. 3 B). These
data strongly suggest that Src or an Src family member is
necessary for Vav2 activation of Rac in vivo.
 
The PH domain is necessary for Vav2 activity
 
The activity of Vav1 is stimulated by phosphoinositide
products of phosphoinositide 3 (PI-3) kinase binding to the
PH domain, however, mutations in the PH domain of Vav1
do not completely inhibit exchange activity and a mutation
in the PH domain of Vav3 does not impair its function
(Han et al., 1998; Movilla and Bustelo, 1999). The role of
the PH domain in Vav2 function is not known. To deter-
mine whether the PH domain is necessary for Vav2 activity
we mutated R425 to G, based on mutations in Vav1 that
disrupt the binding of phosphoinositides (Han et al., 1998).
HEK293T cells were transfected with R425G Vav2 and
Rac1 activation was measured. This construct did not acti-
vate Rac (Fig. 4 A) and or cause lamellipodia (compare Fig.
4 B with 2 A), indicating that unlike Vav1 and Vav3, the
PH domain is required for Vav2 function.
The necessity of the PH domain could reflect a require-
ment for phosphoinositide binding. To determine if the
products of PI-3 kinase are necessary for Vav2 function, we
tested whether wortmannin blocked Vav2-dependent Rac
activation. HEK293T cells were transfected with Vav2 and
Rac activation compared in cells treated with wortmannin
(200 nM) for 1 h to cells left untreated. As shown in Fig. 4
C, wortmannin did not affect Vav2-dependent Rac activa-
tion. These results were confirmed by examining lamellipo-
Figure 1. Activation of GTPases by 
Vav2 expression in vivo. NIH3T3 fibro-
blasts (A, C, and D) or HEK293T cells (B) 
were transfected with Vav2, Vav1, or 
Dbl plus myc-Rac (A), HA-Cdc42 (C), or 
HA-RhoA (D) at a ratio of 3:1 (RhoGEF/
GTPase). The effect of Vav1 and Vav2 
on endogenous Rac was determined in 
HEK293T cells (B). Cells were harvested 
after 24 h and lysates incubated with 
GST-PBD (A–C) or GST-TRBD (D) 
bound to glutathione beads for 40 min at 
4 C and then washed and the proteins 
separated by SDS-PAGE. Activation of 
Rac, RhoA, or Cdc42 was determined by 
Western blotting with Rac, myc, or HA 
antibodies. Total cell lysates (TCL) were 
also Western blotted for expression of 
Vav2 with Vav2 antibody and GTPases 
as described in Material and methods. 
These results are representative of three 
experiments. 
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dia in NIH3T3 cells overexpressing Vav2 after treatment
with wortmannin. Concentrations of wortmannin as high as
1 
 
 
 
M did not inhibit Vav2-mediated lamellipodia, although
the contracted appearance of untransfected cells indicated
that the wortmannin was active (Fig. 4 D). PI-3 kinase is not
required for Vav2 activation of Rac or lamellipodia forma-
tion in contrast to Vav1, where wortmannin partially im-
pairs Vav1-dependent ruffling (Miranti et al., 1998).
 
Mutation of the Vav2 DH domain
 
All exchange factors for Rho family of GTPases contain a
DH domain that is required to catalyze nucleotide exchange.
We wished to make a Vav2 DH mutant that lacked ex-
change activity and thus might function as a dominant nega-
tive to allow us to identify Vav2-dependent functions. Mu-
tations in the DH domain of several RhoGEFs disrupt
catalysis of GDP/GTP exchange (Hart et al., 1994; Liu et
al., 1998; Ma et al., 1998). Based on these mutations, we
mutated R335 to G and the L342/L343 residues to R342/
S343 in the DH domain of Vav2. The R335G mutant func-
tioned very much like wild-type Vav2 in assays of Rac acti-
vation, stimulation of Jnk and induction of lamellipodia
(data not shown), which is somewhat surprising since a sim-
ilar mutant in the Trio DH domain markedly inhibited ex-
change activity in vitro (Liu et al., 1998). The L342R/
L343S mutant did not activate Rac (Fig. 5 A), or Rho (data
not shown) and did not cause lamellipodia in transfected
NIH3T3 cells (Fig. 5 B) or Jnk activation in transfected
COS7 cells (data not shown, see Fig. 7 C).
 
L342R/L343SVav2 does not inhibit formation of 
Vav1-dependent actin structures or Rac activation
 
The purpose of designing a Vav2 DH domain mutant was
to use this reagent as a dominant negative in order to iden-
tify a function for Vav2. L342R/L343SVav2 should be re-
cruited to sites where Rac would be activated by Vav2 and
thereby block recruitment of endogenous Vav2 and thus
Rac activation by endogenous Vav2. However, this con-
struct could act nonspecifically, particularly if it sequestered
Rac. To be certain that any inhibitory effects of L342R/
L343SVav2 were specific for Vav2, we investigated whether
it would block Vav1-mediated Rac activation or lamelli-
podia formation. HEK293T cells were transfected with
OncoVav1 or OncoVav1 and L342R/L343SVav2, and acti-
vation of endogenous Rac was determined using the PBD
assay. L342R/L343SVav2 did not block Vav1-dependent
Rac activation (Fig. 6 A). Similarly, L342R/L343SVav2 co-
expression did not affect the frequency or extent of lamelli-
Figure 2. Vav2 stimulates lamellipodia and Jnk activity. (A) 
NIH3T3 cells were transfected with Vav2, fixed after 24 h, and 
stained for Vav2 expression with the T7 antibody and for actin with 
rhodamine-phalloidin. (B) COS7 cells were transfected with Vav2 
and FLAG epitope–tagged Jnk followed by immunoprecipitation of 
Jnk with FLAG antibody. Jnk activity was determined as described in 
Materials and methods by phosphorylation of GST-jun (top). Cell ly-
sates were Western blotted to determine Jnk (middle) and Vav2 (bot-
tom) expression. These results are representative of four experiments.
Figure 3. Activation of Vav2 is Src-dependent. (A) HEK293T cells 
were transfected with Vav2 or Vav2 and KD and harvested after 24 h. 
Activation of endogenous Rac (PBD) was assayed as described in 
Materials and methods. Total cells lysates (TCL) were also Western 
blotted with T7 antibody for Vav2 expression. (B) NIH3T3 cells were 
transfected with Vav2 and KD Src or Vav2 transfected cells were 
treated with PP2 (2  M) for 30 min or left untreated. The cells were 
fixed and then stained for Vav2 expression with T7 antibody and for 
actin with rhodamine-phalloidin. The arrow indicates the trans-
fected cell. These results are representative of three experiments. 
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podia or stress fibers in OncoVav1 transfected cells (Fig. 6
B). Thus, the L342R/L343SVav2 mutant could function as
a dominant negative specific for Vav2.
 
Vav2 is not necessary for EGF- or PDGF-induced 
ruffling or Jnk activation
 
Tyrosine phosphorylation of Vav family members is impor-
tant for activation in vitro and Vav1, Vav2, and Vav3 are tyro-
sine phosphorylated in response to EGF and PDGF stimula-
tion (Margolis et al., 1992; Schuebel et al., 1996; Pandey et
al., 2000). Therefore, we investigated whether Vav2 might be
necessary for PDGF- or EGF-dependent activation of Rac.
We first confirmed that PDGF and EGF stimulated tyrosine
phosphorylation of Vav2. NIH3T3 or COS7 cells were
treated with PDGF or EGF, respectively. Cells were lysed and
endogenous Vav2 was immunoprecipitated and Western blot-
ted for phosphotyrosine. PDGF and EGF stimulated tyrosine
phosphorylation of Vav2, as has been described previously
(Fig. 7 A; Schuebel et al., 1998; Pandey et al., 2000). To deter-
mine whether Vav2 was necessary for PDGF- or EGF-depen-
dent lamellipodia, NIH3T3 or COS cells were transfected
with L342R/L343SVav2, serum starved, and then treated
with PDGF (15 ng/ml) or EGF (33 nM) for 15 min. The cells
were then fixed and stained for L342R/L343SVav2 expression
using the T7 antibody and for actin with rhodamine phalloi-
din. Expression of L342R/L343SVav2 did not affect the mor-
phology of serum-starved cells and did not block either PDGF
(Fig. 7 B, top) or EGF-dependent lamellipodia (Fig. 7 B, bot-
tom). L342R/L343SVav2 did not inhibit EGF-dependent Jnk
activation either (Fig. 7 C). These results indicate that Vav2
does not mediate EGF- or PDGF-dependent lamellipodia or
EGF-dependent Jnk activation and demonstrate that L342R/
L343SVav2 does not block all Rac-dependent functions.
Growth factor stimulation did result in a perinuclear vesicular
staining pattern of Vav2, which might be explained by inter-
nalization with growth factor receptors (Fig. 7 B).
Figure 4. The PH domain is necessary 
for Vav2 exchange activity. (A) 
HEK293T cells were transfected with 
R425GVav2 and exchange activity for 
endogenous Rac (PBD) was determined 
as described in Materials and methods. 
Total cell lysates (TCL) were also West-
ern blotted for Rac and Vav2 expression 
with Rac and T7 antibodies, respec-
tively. (B) NIH3T3 cells were transfected 
with R425GVav2, fixed 24 h later, and 
stained for R425GVav2 expression with 
T7 antibody and for actin with rho-
damine-phalloidin. The arrow indicates 
the transfected cell. (C) HEK293T cells 
were transfected with Vav2 and treated 
after 24 h with wortmannin (200 nM) for 
1 h. Activation of endogenous Rac (PBD) 
was determined as described in Materi-
als and methods. Total cell lysates were 
Western blotted for Rac and Vav2 ex-
pression using Rac and Vav2 antibodies, 
respectively. (D) NIH3T3 cells were 
transfected with Vav2, and after 24 h the cells were treated with wortmannin (200 nM) for 1 h and then fixed and stained for Vav2 expression 
with T7 antibody and for actin with rhodamine-phalloidin. These results are representative of three experiments.
Figure 5. Vav2 DH mutant lacks ex-
change activity. (A) HEK293T cells were 
transfected with L342R/L343SVav2 and 
HA wild-type Rac, and 24 h later Rac 
activation was determined as described 
in Materials and methods using the PBD 
assay. Total cell lysates (TCL) were also 
Western blotted with HA and Vav2 anti-
bodies to determine protein expression. 
(B) NIH3T3 cells were transfected with L342R/L343SVav2, fixed after 24 h, and stained for Vav2 expression with T7 antibody and for actin 
with rhodamine-phalloidin. The arrows indicate the transfected cells. These results are typical of four experiments. 
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Figure 6. L342R/L343SVav2 does not 
inhibit Vav1. (A) HEK293T cells were 
transfected with OncoVav1 or OncoVav1 
and L342R/L343SVav2 at a DNA ratio of 
1:3 (Vav1/Vav2). 24 h later activation of 
endogenous Rac was determined as de-
scribed in Materials and methods using 
the PBD assay. Total cell lysate (TCL) was 
also Western blotted with Vav2 antibody 
to determine protein expression. (B) 
NIH3T3 cells were transfected with OncoVav1 and L342R/L343SVav2 at a DNA ratio of 1:3 (Vav1/Vav2) and fixed 24 h later. The cells were 
stained for Vav2 expression with T7 antibody and with rhodamine-phalloidin. These results are representative of three experiments.
 
L342R/L343SVav2 mutant blocks 
cell spreading on fibronectin
 
Spreading of cells on fibronectin involves Cdc42-dependent
filopodia formation followed by Rac-dependent lamellipo-
dia and then Rho activation (Clark et al., 1998; Price et al.,
1998). To determine whether Vav2 is necessary for cell
spreading, NIH3T3 cells were transfected with L342R/
L343SVav2 and 24 h later they were trypsinized, allowed to
recover, and then plated onto fibronectin. At various time
points the cells were fixed and stained for Vav2 expression
and for actin. The number of cells that were unspread,
partially spread, or fully spread was then determined.
L342R/L343SVav2 significantly impaired the spreading of
NIH3T3 cells on fibronectin, indicating that Vav2 is neces-
sary for this process (Fig. 8 A).
To determine why cells expressing L342R/L343SVav2
failed to spread on fibronectin, we examined these cells us-
ing live-time microscopy. NIH3T3 cells were transfected
with L342R/L343SVav2 and pEGFP to visualize the trans-
fected cells by EGFP expression. The cells were trypsinized,
rested, and plated onto fibronectin and images were cap-
tured at various time points. The normal sequence of cell
spreading can be seen in untransfected cells in which cells
extend filopodia, followed by lamellipodia (Fig. 8 B, white
arrow). Cells transfected with L342R/L343SVav2 (Fig. 8 B,
black arrows) failed to form lamellipodia or spread. Exami-
nation of L342R/L343SVav2-expressing cells at higher
power by phase contrast of live cells or actin staining of fixed
cells showed that filopodia did form and contained actin
(Fig. 8 C). Untransfected cells formed filopodia, but also
formed lamellipodia and spread (Fig. 8 C). These results
suggest that Vav2 is necessary for lamellipodia formation
and thus Rac activation in response to integrin signals.
Since tyrosine phosphorylation has been correlated with
Vav family activity, we also determined whether plating of
NIH3T3 cells on fibronectin induced tyrosine phosphoryla-
tion of Vav2. NIH3T3 cells were trypsinized, rested, and
then plated onto fibronectin-coated plates. At the times after
plating, Vav2 was immunoprecipitated and tyrosine phos-
phorylation of Vav2 and total cell lysate was assessed by
Western blotting. We detected a decrease in tyrosine phos-
phorylation of Vav2 at early time points, followed by a
return to basal levels (Fig. 8 D). Vav2 protein levels were
similar for each time point (data not shown). Tyrosine
phosphorylation of proteins in the total cell lysate increased
in response to plating as expected.
 
Discussion
 
Vav2 is a ubiquitously expressed member of the Vav family
of RhoGEFs, whose function is largely unknown. We deter-
mined the GTPases activated by Vav2 overexpression, the
domains necessary for its activity and have used a dominant
negative construct to investigate the function of Vav2. Sev-
eral groups have shown that either NH
 
2
 
-terminal trunca-
tion of Vav2 or coexpression of wild-type Vav2 with acti-
vated Lck was necessary for Vav2-dependent lamellipodia
(Schuebel et al., 1998; Abe et al., 2000). In contrast, and
similar to the results of Liu and Burridge (2000), we found
that overexpression of wild-type Vav2 was sufficient to in-
duce lamellipodia and activate Jnk. Using baculovirus-derived
recombinant protein, Schuebel et al. (1998) found that
Vav2 activates RhoA, RhoB, and RhoG, but not Rac1 or
Cdc42, as determined by exchange assays in vitro. Abe et al.
(2000) used truncated Vav2 produced in bacteria and found
that it catalyzed exchange for Rac1, RhoA, and Cdc42 in
vitro. Liu and Burridge (2000) found that Vav2 expressed in
CHO cells activates Rac1, RhoA, and Cdc42 in vivo. We
found that Vav2 activates Rac1 and, to a lesser extent,
RhoA, but has a minimal effect on Cdc42 in HEK293T or
NIH3T3 cells. The varying results from these studies likely
reflect both differences between in vitro and in vivo assays
and cell-specific effects that may influence the ability of
Vav2 to activate particular GTPases in vivo, such as colocal-
ization and GAP activity. Since Vav2 activates RhoG in
vitro (Schuebel et al., 1998) and RhoG can activate both
Cdc42 and Rac (Gauthier-Rouviere et al., 1998), we cannot
rule out the possibility that the effects we detect are medi-
ated by RhoG. However, the lack of Cdc42 activation in our
experiments argues against this possibility. In contrast to
both Schuebel et al. (1998) and Liu and Burridge (2000) we
did not detect an increase in stress fibers in cells overexpress-
ing Vav2. This could reflect either a difference in RhoGAP
activity in the cell lines or the extent of Rho activation.
The tyrosine kinases Syk, Zap70, and Janus kinase likely
phosphorylate and activate Vav1 in vivo, but the kinase(s)
that stimulate Vav2 in vivo are not known. Inhibition of
Vav2-dependent Rac exchange and lamellipodia by both
KD Src and the Src inhibitor PP2 indicate that Src is neces-
sary for the activity of overexpressed Vav2. Therefore, it is
likely that Src, or a family member, is also necessary for the
function of endogenous Vav2.
All RhoGEFs contain a PH domain immediately COOH-
terminal to the DH domain. A mutation in the PH domain 
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of Vav2 predicted to disrupt phosphoinositide binding based
both on the crystal structure of PH domains and the effects
of a similar mutation in Vav1 (Ferguson et al., 1995;
Hyvonen and Saraste, 1997; Han et al., 1998) lacks ex-
change activity, indicating that the PH domain of Vav2 is
necessary for its function. This is in contrast to Vav1 and
Vav3, where mutation of the PH domain does not affect ex-
change activity (Han et al., 1998; Movilla and Bustelo,
1999). Some exchange factors appear to require the PH do-
main to properly bind the GTP binding protein (Soisson et
al., 1998), but the PH domain could be required to interact
with phosphoinositides. However, we found that the PI-3 ki-
nase is not necessary for Rac activation by overexpressed
Vav2, in apparent contrast to Vav1, where wortmannin par-
tially inhibits lamellipodia in cells cotransfected with Syk
and Vav1 (Miranti et al., 1998). It is likely that PI-3 kinase
products are not required for the activity of endogenous
Vav2, but we cannot exclude the possibility that PI-3 kinase
may further stimulate activated Vav2 or play a role in local-
ization. Neither have we excluded the possibility that PtdIns-
4,5-P
 
2
 
 is necessary for Vav2 exchange activity or that a PH
domain–dependent protein–protein interaction is required.
We mutated the DH domain of Vav2 to develop a con-
struct that would allow us to investigate the function of en-
dogenous Vav2 using a dominant negative approach. The
R335 to G mutant retained exchange activity, but the dou-
ble mutation of L342/L343 to R/S, respectively, eliminated
Vav2 exchange activity for both Rac1 and RhoA. This mu-
tant did not activate Jnk or induce lamellipodia, strongly in-
dicating that the DH domain is necessary for these functions
of Vav2. To determine if this mutant could function as
a specific dominant negative, we determined whether it
blocked Vav1-dependent nucleotide exchange for Rac or ac-
tin organization and found that it did not. These results in-
dicate that the DH mutant of Vav2 does not sequester Rac
and thereby block all Rac-dependent events.
Since Vav2 is tyrosine phosphorylated in response to EGF
and PDGF stimulation, we thought that Vav2 might be
necessary for stimulation of Rac and thus growth factor–
induced lamellipodia and Jnk activation. However, L342R/
L343SVav2 Vav2 did not block lamellipodia induced by ei-
ther PDGF or EGF, indicating that Vav2 is not necessary
for Rac activation by these growth factors. L342R/
L343SVav2 did not block Jnk activation by EGF. Tyrosine
phosphorylation of Vav2 in response to growth factor treat-
ment may reflect activation of Vav2 for a function other
than stimulation of lamellipodia or Jnk activation, or it
could also be inhibitory.
Cell spreading requires activation of Cdc42 followed by
Rac and then Rho (Price et al., 1998). L342R/L343SVav2
blocked the spreading of fibroblasts on fibronectin. Cells ex-
pressing L342R/L343SVav2 did not form lamellipodia, in-
dicating that L342R/L343SVav2 acts as a dominant nega-
 
Figure 7.
 
Vav2 is not necessary for PDGF-dependent ruffling or 
EGF-dependent Jnk activation.
 
 (A) NIH3T3 cells were stimulated 
with PDGF or COS7 cells were stimulated with EGF and immuno-
precipitations were done with preimmune serum (PI) or Vav2 anti-
body (Vav2). The proteins were separated by SDS-PAGE and tyrosine 
phosphorylation of Vav2 was determined by Western blotting. (B) 
NIH3T3 or COS7 cells were transfected with L342R/L343SVav2, se-
rum-starved, and then NIH3T3 cells were stimulated with PDGF 
(top) and COS7 cells were stimulated with EGF (bottom). Cells were 
stained for Vav2 expression with T7 antibody and with rhodamine-
phalloidin. The left panels are quiescent cells expressing L342R/
L343SVav2, the middle panels are growth factor–stimulated cells 
expressing L342R/L343SVav2, and the right panels are untrans-
fected cells stimulated with growth factor. (C) COS7 cells were 
transfected with L342R/L343SVav2 and FLAG-Jnk. The cells were 
serum starved and stimulated with EGF and Jnk activity ([
 
32
 
P]GST-
jun) was determined as described in Material and methods. Cell ly-
sates were also western blotted with FLAG antibody to determined 
Jnk expression and with T7 antibody to determine Vav2 expression. 
These results are representative of four experiments. Bar 
 
 
 
 10 
 
 
 
m. 
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tive to block Rac activation by integrins and thus that Vav2
is required for integrin activation of Rac during cell spread-
ing. Since these cells form filopodia and we detected mini-
mal activation of Cdc42 by Vav2, it is likely that another
RhoGEF activates Cdc42 in response to integrin activation.
Since we find that Vav2 is necessary for cell spreading and
Src activity is necessary for Vav2 activation of Rac and
lamellipodia formation, our data suggest a model of Rac ac-
tivation by integrins that depends on Src phosphorylation of
Vav2. Src is known to be important in cell spreading, al-
though some evidence indicates the kinase activity of Src
may not be required (Kaplan et al., 1995). In studies in
which Src kinase activity did not appear to be necessary for
spreading, phosphorylation of focal adhesion proteins was
increased, whereas in cells derived from the Src
 
 
 
/
 
 
 
/Yes
 
 
 
/
 
 
 
/
Fyn
 
 
 
/
 
 
 
 triple knock-out tyrosine phosphorylation of focal
adhesion proteins is minimal (Klinghoffer et al., 1999).
These results suggest that some level of Src family kinase ac-
tivity is necessary for adherence and spreading, which could
have been provided by Yes or Fyn in Src
 
 
 
/
 
 
 
 cells. We did
not detect an increase in tyrosine phosphorylation of Vav2
in response to plating of NIH3T3 cells on fibronectin, con-
firming the results of Liu and Burridge (2000) and Moores
et al. (2000). This may reflect concomitant dephosphoryla-
tion of inhibitory sites and phosphorylation of sites that
stimulate exchange activity, with little net change in total ty-
Figure 8. Effect of L342R/L343SVav2 on cell spreading. (A) NIH3T3 cells were transfected with vector alone or L342R/L343SVav2. 24 h af-
ter transfection they were trypsinized, allowed to recover, and then plated on fibronectin-coated coverslips. 15 or 60 min after plating the 
cells were fixed and stained for Vav2 expression with T7 antibody and with rhodamine-phalloidin. Cells were counted (100 per condition) 
and scored for spreading: unspread (black bar), partially spread (crossed bar), or fully spread (back-slash bar). Values are expressed as percent 
of total cells counted and represent the mean   SEM of four experiments. (B) NIH3T3 cells were transfected with pEGFP and vector only, or 
L342R/L343SVav2 at a DNA ratio of 1:3 (pEGFP/Vav2 or vector). Cells were trypsinized 24 h after transfection, allowed to recover, and then 
plated on fibronectin. Cell spreading was monitored by phase contrast microscopy. Photographs were taken at 0, 10, 20, and 40 min (un-
transfected cell, white arrow; transfected cells, black arrows). These results are typical of 25 cells examined from 3 separate experiments. (C) 
NIH3T3 cells were transfected with pEGFP and L342R/L343SVav2, trypsinized 24 h later, allowed to recover, and then plated onto fibronec-
tin-coated coverslips. Cells were examined for the presence of filopodia by phase contrast (left, black arrows indicate filopodia) or fixed and 
stained with rhodamine-phalloidin (middle). Untransfected cells were also plated and stained with rhodamine-phalloidin (right). (D) NIH3T3 
cells were trypsinized, allowed to rest, then plated on fibronectin as described in Materials and methods. Cells were harvested at 0, 20, 40, 
and 60 min after plating, endogenous Vav2 was immunoprecipitated and tyrosine phosphorylation was determined by Western blotting. To-
tal cell lysates (TCL) were also Western blotted for phosphotyrosine. These results are representative of three experiments. Bars, 10  m. 
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rosine phosphorylation. It is also possible that integrin-
dependent activation of Vav2 is primarily due to cellular local-
ization involving the PH or SH2 or SH3 domains. Based on
the induction of lamellipodia in cells overexpressing Vav2,
assays of GTPase activation in vivo and the ability of a dom-
inant negative Vav2 to block lamellipodia formation in cells
plated on fibronectin, we conclude that Vav2 activates Rac
in vivo and is necessary for cell spreading.
 
Materials and methods
 
Plasmids
 
A Vav2 mammalian expression vector was constructed by subcloning the
EcoRI-KpnI fragment of Vav2 in Bluescript (pBS) into EcoRI-KpnI–digested
pCMV5. An oligonucleotide containing the sequence for the T7 epitope
was designed with SplI-KpnI sites and ligated into SplI-KpnI–digested Vav2
in pCMV5 to provide a COOH-terminal epitope tag. A GST fusion protein
containing the COOH terminus of Vav2 was constructed by subcloning the
BglII-NotI fragment of Vav2 in pBS into pGEX4T2 (Amersham Pharmacia
Biotech). Mutations in the DH and PH domains were generated in T7
epitope–tagged Vav2 in pCMV5 using the Transformer site–directed mu-
tagenesis kit (CLONTECH Laboratories, Inc.). The L342R/L343S mutant was
made by changing residue L342 (codon CTC) and L343 (codon TTG) to R
(codon CGC) and S (codon TCG), respectively. The PH domain mutant
(R425G) was made by mutating residue R425 (codon AGG) to G (codon
GGG). The mutations were confirmed by sequencing the constructs. The
GST fusion protein of p21 binding domain of PAK was obtained from Dr.
Gary Bokoch (The Scripps Research Institute, La Jolla, CA) and the GST fu-
sion protein of the RBD of rhotekin was obtained from Dr. Martin Schwartz
(The Scripps Research Institute, La Jolla, CA). Vav1 was obtained from Dr.
Stephen Burakoff (Dana-Farber Cancer Institute, Boston, MA) and Dbl was
obtained from Dr. Richard Cerione (Cornell University, Ithaca, NY). Consti-
tutively active mammalian Y527F Src was a gift from Dr. Paul Kaplan (Af-
fymetrix, Inc., Santa Clara, CA). KD mammalian Src K295R/Y527F (KD Src)
was a gift from Dr. Joan Brugge (Harvard Medical School, Boston, MA).
 
Antibodies
 
The Vav2 antiserum was raised in rabbits using the GST fusion protein of
the Vav2 COOH terminus as the antigen. Sera did not recognize Vav1 or
Vav3. HA (12CA5) antibody was purchased from Boehringer. T7 antibody
was purchased from Novagen. FLAG (M2) monoclonal antibody was pur-
chased from Sigma-Aldrich. Antiphosphotyrosine monoclonal antibody
was a gift from Dr. Thomas Roberts (Dana Farber Cancer Institute, Boston,
MA). Rac and Rho monoclonal antibodies were purchased from Transduc-
tion Laboratories.
 
Cell culture and transfections
 
NIH3T3 and COS7 cells were grown in DME containing 10% (vol/vol) calf
serum. HEK293T cells were grown in DME with 10% (vol/vol) heat-inacti-
vated fetal calf serum. Transient transfections were done using Superfect
(QIAGEN) or Lipofectamine Plus Reagent (GIBCO BRL) according to the
manufacturer’s guidelines.
 
Cell stimulation and immunoprecipitation
 
PP2 was used at a concentration of 2 
 
 
 
M for 30 min. In experiments in
which growth factor effects on tyrosine phosphorylation of Vav2 were de-
termined, cells were serum starved for 16 h followed by treatment with
PDGF (40 ng/ml) or EGF (33 nM) for 15 min. PDGF was used at a concen-
tration of 15 ng/ml for immunofluorescence studies. Immunoprecipitations
were done by first washing the cells in cold PBS and then lysing them in a
buffer containing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP40, 10
mM EDTA, 0.2 mM sodium orthovanadate, 10% glycerol, 4 
 
 
 
g/ml leupep-
tin, 4 
 
 
 
g/ml pepstatin, and 4 
 
 
 
g/ml AEBSF. Lysates were cleared by centrif-
ugation and incubated with antibody and protein A–Sepharose beads for
3 h at 4
 
 
 
C. The beads were washed three times in lysis buffer and associated
proteins were resolved by SDS-PAGE followed by transfer to Immobilon-P
membrane (Millipore). Membranes were blocked with 2% (wt/vol) BSA in
Tris-buffered saline. The blots were probed with primary antibody and
then with horseradish peroxidase–conjugated secondary antibody (Boeh-
ringer) and visualized by enhanced chemiluminescence (Dupont) accord-
ing to the manufacturer’s instructions.
 
Microscopy
 
NIH3T3 cells on glass coverslips were fixed in 3% paraformaldehyde-PBS
for 10 min, permeabilized in 0.2% Triton X-100 for 2 min, and blocked in
2% BSA-PBS for 10 min. The cells were incubated with primary antibodies
for 1 h, washed, and then incubated with secondary antibodies (Jackson
ImmunoResearch Laboratories) and rhodamine-phalloidin (100 ng/ml;
Sigma-Aldrich) for 1 h. Coverslips were mounted onto slides with Fluoro-
mount-G (Southern Biotechnology Associates, Inc.). Images of both live
and fixed cells were acquired using a microscope (Diaphot 300; Nikon)
mounted with a camera (SenSys CCD; Photometrics) and processed using
Vaytek imaging software.
 
Jnk kinase assays
 
COS7 cells were transfected and then lysed 24 h later in a buffer containing
40 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA, 25 mM NaF, 1 mM
sodium vanadate, 4 
 
 
 
g/ml aprotinin, and 4 
 
 
 
g/ml leupeptin. FLAG-Jnk was
immunoprecipitated from cleared lysates with M2 antibody and protein
G–sepharose beads for 1 h at 4
 
 
 
C. Beads were washed and kinase activity
was assayed in 30 
 
 
 
l of kinase buffer (25 mM Hepes, pH 7.6, 20 mM
MgCl
 
2
 
, 20 mM 
 
 
 
-glycerophosphate, 0.1 mM sodium vanadate, 2 mM DTT),
20 
 
 
 
M ATP, 5 
 
 
 
Ci [
 
 
 
-
 
32
 
P]ATP, and 5 
 
 
 
g GST-
 
c
 
-jun. Reactions were incu-
bated at 30
 
 
 
C for 30 min and terminated by the addition of 10 
 
 
 
l 5
 
 
 
 Laem-
mli buffer (Ma et al., 1998). The proteins were separated by SDS-PAGE and
phosphorylation quantified with a Molecular Imager (Bio-Rad Laboratories).
 
GTPase activity assays
 
GST fusion proteins of PBD (GST-PBD; Sander et al., 1998) or rhotekin
(GST-RBD; Ren et al., 1999) were as described by (O’Connor et al., 2000).
For Rac and Cdc42 activity assays, cells were lysed 24 h after transfection
in a buffer containing 20 mM Hepes, pH 7.5, 100 mM NaCl, 0.5% NP-40,
10 mM MgCl
 
2
 
, 10 mM 
 
 
 
-glycerophosphate, 10% glycerol, 4 
 
 
 
g/ml leu-
peptin, and 4 
 
 
 
g/ml pepstatin (Sander et al., 1998). Lysates were cleared
and incubated with GST-PBD (to assess Rac or Cdc42 activation) or GST-
TRBD (to assess Rho activation) bound to glutathione agarose beads for 30
min at 4
 
 
 
C. For the Rho activity assay, lysates were diluted 1:1 in a buffer
containing 50 mM Tris, pH 7.2, 500 mM NaCl, 1% Triton X-100, 0.5% so-
dium deoxycholate, 0.1% SDS, 10 mM MgCl
 
2
 
, 10 
 
 
 
g/ml leupeptin, 10 
 
 
 
g/
ml aprotinin, 1 mM PMSF. The beads were washed three times in lysis
buffer and analyzed for bound Rac, Cdc42 and Rho by Western blotting.
 
Cell spreading on fibronectin
 
Plates or coverslips were coated with fibronectin (10 
 
 
 
g/ml) for 2 h at
37
 
 
 
C. Cells were prepared for plating by trypsinization and then were
washed once in DME with 1 mg/ml soybean trypsin inhibitor. Cells were
pelleted, washed twice with DME, and then resuspended in DME and al-
lowed to recover for 40 min at 37
 
 
 
C. Cells were then plated onto fibronec-
tin-coated coverslips or plates. Cells were fixed at 15 and 60 min after plat-
ing and stained for Vav2 with T7 antibody followed by AMCA anti–mouse
secondary antibody and rhodamine-phalloidin. Vav2-expressing cells
were classified as unspread (adherent with no projections), partially spread
(adherent with limited lamellipodia), and fully spread.
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